Evidence map›Paper›PMID 34972817›Full record

ArticleScientific reports2021

Reduction in trabecular meshwork stem cell content in donor eyes with primary open angle glaucoma.

Yogapriya Sundaresan, Lakshmi Priya Manivannan, Shanthi Radhakrishnan, Krishnadas Subbiah Ramasamy, Muthukkaruppan Veerappan, Gowri Priya Chidambaranathan

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Transplantation of human trabecular meshwork stem cells induces cell proliferation and intraocular pressure reduction in a cell loss model of glaucoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. iPSCs-Based Therapy for Trabecular Meshwork.Handbook of experimental pharmacology · 2023
    Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yogapriya SundaresanDepartment of Immunology and Stem Cell Biology, Aravind Medical Research Foundation, Madurai, 625020, Tamil Nadu, India.
Lakshmi Priya ManivannanDepartment of Immunology and Stem Cell Biology, Aravind Medical Research Foundation, Madurai, 625020, Tamil Nadu, India.
Shanthi RadhakrishnanDepartment of Pathology, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Madurai, 625020, Tamil Nadu, India.
Krishnadas Subbiah RamasamyGlaucoma Clinic, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Madurai, 625020, Tamil Nadu, India.
Muthukkaruppan VeerappanDepartment of Immunology and Stem Cell Biology, Aravind Medical Research Foundation, Madurai, 625020, Tamil Nadu, India.
Gowri Priya ChidambaranathanDepartment of Immunology and Stem Cell Biology, Aravind Medical Research Foundation, Madurai, 625020, Tamil Nadu, India. gowri@aravind.org.
Aravind Eye Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously identified and characterized human trabecular meshwork stem cells (TMSCs) based on high expression of ABCG2/p75 positivity and high nucleus to cytoplasmic ratio. These TMSCs expressing high ABCG2 and p75 were located to the insert region of the human TM. Additionally, we demonstrated an age-related reduction in the TMSC content which was significantly associated with TM cell loss. In continuation, this study was aimed to determine the TMSC content in glaucomatous donor eyes wherein a drastic reduction in TM cellularity has already been reported. Anterior segments from known glaucomatous (n = 6) and age-matched normal (n = 8) donors were dissected into four quadrants. A minimum of three sections from each quadrant were used for histopathological analysis as well as immunostaining. Analysis of hematoxylin and eosin-stained sections from glaucomatous tissues revealed a decrease in total TM cellularity, thickening of trabecular beams, fusion of trabeculae, absence of patent Schlemm's canal compared to age-matched controls. In addition, the TM thickness at various positions of the meshwork and the coronal as well as the meridional diameters of the Schlemm's canal were observed to be significantly reduced in glaucomatous eyes. Further, sections from both the groups were immunostained for universal stem cell marker ABCG2 and neural crest derived stem cell marker p75. The images were acquired using Leica SP8 confocal microscope. Quantification of total TM cellularity based on nuclear counterstain (mean ± SD) using ImageJ identified 69.33 ± 12.77 cells/section in control eyes. In glaucomatous donors, the TM cellularity was found to be reduced significantly to 41.83 ± 9.0 (p = 0.0007). In addition, a reduction in the percentage of TMSCs (cells with high ABCG2 expression and p75 positivity) was evident in glaucomatous donors (0.14 ± 0.17%) compared to age-matched controls (4.73 ± 5.46%) (p = 0.064). Thus, the present study confirmed the significant decline in TM cellularity and a reducing trend in the TMSC content, though this reduction was non-significant in glaucomatous donor eyes. Further studies are essential to elucidate the role of TMSCs in the pathogenesis of primary open angle glaucoma.

Indexed as

Tissue DonorsAdult Stem CellsAgedAged, 80 and overBiomarkersCell CountFemaleGlaucoma, Open-AngleHumansImmunohistochemistryMaleMicroscopy, ConfocalMiddle AgedStem CellsTrabecular MeshworkBiomarkers

Identifiers

PMID34972817
PMCPMC8720087
OpenAlexW4206619636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.